Ovr110 antibody compositions and methods of use
The invention provides isolated anti-head and neck, ovarian, pancreatic, lung, endometrial or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell by contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal by administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.
1. A method of killing head and neck cancer cell, wherein the head and neck cancer is adenoid cystic carcinoma, comprising contacting the cancer cell with an anti-Ovr110 antibody conjugated to a cytotoxic agent, thereby killing the cancer cell.
2. The method of claim 1 , wherein the localization of the adenoid cystic carcinoma is selected from the group consisting of the tongue, parotid gland, nose, palate, skin, neck, submandibular gland, glottis, sinus, epiglottis, buccal space, nerves, larynx, mouth, pharynx, and cheek.
3. The method of claim 1 , wherein the cytotoxic agent is a toxin selected from the group consisting of maytansinoid, ricin, saporin and calicheamicin.
4. The method of claim 1 , wherein the antibody is administered in conjunction with at least one chemotherapeutic agent.
5. The method of claim 4 , wherein the chemotherapeutic agent is paclitaxel or derivatives thereof.
6. The method of claim 1 , wherein the antibody is a monoclonal antibody.
7. The method of claim 1 , wherein the antibody is a human antibody.
8. The method of claim 1 , wherein the antibody is a chimeric antibody.
9. The method of claim 1 , wherein the antibody is an antibody fragment comprising an antigen binding domain.
10. The method of claim 1 , wherein the antibody is a humanized antibody.